Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Kafrit Industries on acquisition of Addvanze
Mandate

Vinge advises Kafrit Industries on acquisition of Addvanze

May 11, 2021 Employment and Benefits Banking and Finance Intellectual Property IT, Telecommunications and Outsourcing M&A Real Estate and Construction Commercial Agreements

Vinge advises Kafrit Industries (1993) Ltd on acquisition of Addvanze AB.

Kafrit Industries (1993) Ltd is an innovative and world leading producer of customized Masterbatches and Compounds for the plastic industry. For over 40 years Kafrit and its subsidiaries have been selling unique products and giving added value to well known customers around the world. Addvanze AB is a leading producer of the masterbatch in Europe.

Vinge’s team consisted of, among others, partners Christina Kokko and Matthias Pannier and associates Isabelle Jengsell and Amanda Steen (M&A), Isabell Nielsen (Agreements), Ludvig Wettergren and Karl-Gustaw Tobola (Banking and finance), Sara Strandberg (Employment), Sofia Bergenstråhle (IPR), Karl-Hugo Engdahl (IT/GDPR), Lina Österberg (Real Estate and environment) and VDR assistant Nathalie Hughes.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025